Status:
COMPLETED
Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Lead Sponsor:
Singapore General Hospital
Collaborating Sponsors:
National Medical Research Council (NMRC), Singapore
Conditions:
Acute Myeloid Leukemia
Myelodysplastic Syndrome, High Grade
Eligibility:
All Genders
12-75 years
Phase:
PHASE1
PHASE2
Brief Summary
A phase I/II study to explore the feasibility and efficacy of autologous CIK cells in patients with acute myeloid leukemia (AML)/ high grade myelodysplastic syndrome (MDS) 1. Group 1: As adjuvant the...
Detailed Description
This is a Phase I /II study on the feasibility / efficacy of adoptive immunotherapy with autologous CIK cells for the following 2 groups of patients who have AML or high grade MDS : 1. Group 1 patien...
Eligibility Criteria
Inclusion
- For Group 1: AML or MDS post autologous peripheral blood or marrow stem cell transplant.
- For Group 2: High grade MDS ( RAEB or RAEBIT ) or AML, whom the haematologist in charge has assessed and deemed unfit for chemotherapy with curative intent.Patients must have fairly stable white cell count requiring only low dose or no myelosuppressive medication
- Patients must understand the trial nature of this treatment and accept the possible absence of benefit.
Exclusion
- uncontrolled infection
- life expectancy less than 6 weeks.
- Contraindication to undergo one session of leukapheresis for PBMNC harvesting
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00394381
Start Date
October 1 2006
End Date
January 1 2012
Last Update
February 10 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Singapore General Hospital
Singapore, Singapore, 169608